[K-Bio Global Phase 3] Fred Kim, Head of AriBio US: "AR1001 Aims to Become the First-Line Therapy for Early Alzheimer’s"

Global Phase 3 results to be unveiled in November; focus shifts to monotherapy efficacy and tangible patient benefits.

Targeting FDA approval submission in 2027, with a strategy to offer more affordable pricing than existing antibody therapies.

AriBio is developing its oral Alzheimer’s disease candidate, "AR1001," as a primary treatment option for patients in the early stages of the disease. The company’s strategy is to confirm the efficacy of the drug as a monotherapy in its global Phase 3 clinical trial while enhancing treatment accessibility through superior dosing convenience and price competitiveness.

Fred Kim, Head of AriBio’s U.S. operations, emphasized during a press Q&A session that evaluating AR1001’s clinical results requires looking beyond mere statistical significance to the actual, tangible changes experienced by patients. The core of his message is that it is essential to demonstrate how much the drug can delay cognitive decline while meeting regulatory standards for approval.

The global Phase 3 trial, dubbed "POLARIS-AD," involves 1,535 patients with early-stage Alzheimer’s across 13 countries. Key results are scheduled to be unveiled for the first time at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston on November 16, 2026. Based on these data, the company is preparing to file for U.S. Food and Drug Administration (FDA) approval in 2027, with an eye toward market authorization in 2028.

The following is a summary of the Q&A session, curated to reflect the core objectives of the participants.

Q. What is the most critical aspect to look for in the Phase 3 results to be released in November?

Kim: We are focusing on the statistical significance that determines the success of the trial. Meeting established standards is essential for regulatory approval and commercialization; it is the only way to deliver the medication to patients.

From the patient's perspective, what truly matters is how these results translate into daily life. Indicators like how much the drug can slow cognitive decline and how much time patients can gain to continue living as themselves are the metrics that resonate most. When we release the results, we plan to explain both the clinical significance of the data and the actual impact on patients.

Q. Why emphasize the results of the monotherapy group alongside the overall patient population?

Kim: Our goal is to develop AR1001 as a first-line therapy. We want patients diagnosed with mild cognitive impairment (MCI) due to Alzheimer’s to have access to a safe and convenient treatment option from the very beginning.

To achieve this, it is crucial to obtain significant results in the monotherapy group, independent of other Alzheimer’s treatments. Through this analysis, we aim to establish the clinical foundation for its use as an initial treatment.

Q. What is the scope of the patient population targeted for the first approval?

Kim: We are targeting early-stage Alzheimer’s. This includes both mild cognitive impairment due to Alzheimer’s and mild dementia. Mild dementia represents a stage where cognitive decline leads to greater difficulty in daily living.

Our initial goal is to secure approval within this range. To expand the scope later, we will need to build evidence through additional clinical trials and data accumulated in real-world clinical settings.

Q. Is the target of submitting for approval in 2027 and obtaining authorization in 2028 a schedule discussed with the FDA?

Kim: The timeline we presented is based on standard regulatory review periods. We are already preparing the submission materials and plan to proceed with the filing process following the release of the key results in 2026.

We are also working with Fosun Pharma to explore ways to shorten the timeline. If we can utilize pathways such as priority review, there is a possibility of reducing the review duration. We plan to meet with the FDA after the main results are announced and will provide updates as the process moves forward.

Q. What is the plan for pricing?

Kim: Existing Alzheimer’s antibody treatments are priced in the range of 40 million to 60 million KRW per year. We plan to supply AR1001 at a lower price point. Because the specific price must be determined in consultation with our partners in each country, we will disclose details as they are finalized.

Q. At what stage should patients start taking the drug, and what is the expected duration of treatment?

Kim: As mentioned, the first goal is early-stage Alzheimer’s, including MCI and mild dementia. Expanding the application will require further evidence gathering.

Regarding the duration, Chairman Jae-Jun Chung added that Alzheimer’s treatments are typically taken continuously once started—often until the end of the patient's life. He noted that this is exactly why we are focused on developing AR1001 as a first-line therapy.

AriBio’s goal is to reduce the burden on patients and their families with an oral medication taken once daily at home. After securing clinical evidence in early-stage Alzheimer’s, our plan is to develop it into a treatment that can be utilized not only in specialized hospitals but also at primary care clinics.